About Exelixis Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.exelixis.com/
Frequently Asked Questions
What is the 52-week range for EXEL?
The 52-week high is $61.14 and the 52-week low is $33.76.
What is the P/E ratio for EXEL?
The Price to Earnings (P/E) ratio is 16.90.
What is the dividend yield for EXEL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 42.49%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 35.33%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.44.
Analyst Recommendation Trends
Wall Street analyst consensus for EXEL over the last few months:
Latest EXEL News
These IBD 50 Stocks Are Stalled. That Could Be A Good Thing.
A few IBD 50 stocks are showing unusually narrow trading.
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select biotechnology stocks with more reasonable finances can draw interest. This article breaks down three biotech stocks from a curated screener that aims to balance high upside with some measure of financial discipline. The stocks covered below are just a small...
Exelixis Shares Rising on CABOMETYX Revenue
Big Money pushes Exelixis, Inc. (EXEL) shares higher by 149% since 2017.
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?
Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer
Exelixis (NasdaqGS: EXEL) said the FDA has extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer. The agency lengthened the decision timeline after Exelixis submitted a major amendment with updated safety and efficacy data. The extended FDA review tied to new zanzalintinib safety and efficacy information only captures part of what matters today. Check out 4 other big wins that Exelixis investors should know about. To put this regulatory update in context,...
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B
Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027. The September 10 notification followed an FDA request for updated safety and efficacy information. The submitted data were classified as a major amendment. The […]
Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Exelixis, Inc. (EXEL) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsMichael Morrissey - CEO,...
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki
Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)
Exelixis, Inc. is downgraded from Buy to Hold after a 47% rally despite negative business developments. Click here to read an analysis of stock now.
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises
Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies. Speaking at a company event, Andrew Peters, Exelixis’ senior vice p
Exelixis: The FDA Delay Costs Less Than The Market Thinks
The FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure or safety signal was disclosed. Read why EXEL stock is a Buy.
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread.
Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay
Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment.
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months
Exelixis Inc (NASDAQ:EXEL) shares fell 3. 5% in premarket trading Friday after the company said the US Food and Drug Administration extended the review period for its new drug application for zanzalintinib by three months.
Exelixis Announces Three-Month FDA Review Period Extension For Its Zanzalintinib New Drug Application In Combination With Atezolizumab For The Treatment Of Metastatic Colorectal Cancer
In response to an FDA information request, Exelixis had submitted updated safety and efficacy data, which the FDA has deemed a major amendment. The updated Prescription Drug User Fee Act action date is March 3, 2027.
Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Exelixis, Inc. (EXEL) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 8:40 AM EDTCompany ParticipantsAndrew Peters - Senior Vice...
ServiceNow Leads Five Stocks To Watch Near Buy Points
Meanwhile, several stocks showed bullish signs, including software giant ServiceNow. Digital bank Dave Inc., commodities trading platform Marex Group, senior living REIT Welltower and cancer treatment developer Exelixis round out the list of stocks to watch in or near buy zones. ServiceNow is in a buy zone after breaking out of a cup base with a buy point of 139.20 on Aug. 28, reclaiming the entry on Sept. 2.
IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out
Exelixis is Friday's IBD Stock Of The Day. Shares have recovered from a post second-quarter drop and are now trading in a buy zone.
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-10 | Beckerle Mary C | -9,812 | $53.66 | $526,512 |
| 2026-06-01 | Eckhardt Sue Gail | -9,812 | $50.14 | $491,974 |
| 2026-06-01 | WYSZOMIERSKI JACK L | -3,925 | $50.55 | $198,409 |
| 2026-05-27 | Eckhardt Sue Gail | +8,367 | - | - |
| 2026-05-27 | Heyman Tomas J. | +8,367 | - | - |
| 2026-05-27 | Caligan Partners LP | +19,133 | - | - |
| 2026-05-27 | Oliver Bob | +8,367 | - | - |
| 2026-05-27 | Smith Julie | +8,367 | - | - |
| 2026-05-27 | Freire Maria C | +8,367 | - | - |
| 2026-05-27 | Beckerle Mary C | +8,367 | - | - |
| 2026-05-27 | PAPADOPOULOS STELIOS | +8,367 | - | - |
| 2026-05-27 | POSTE GEORGE | +8,367 | - | - |
| 2026-05-27 | WYSZOMIERSKI JACK L | +8,367 | - | - |
| 2026-05-26 | Aftab Dana | -43,451 | $50.35 | $2,187,758 |
| 2026-05-20 | Haley Patrick J. | -32,110 | $49.81 | $1,599,399 |
| 2026-05-18 | Hefti Brenda | -6,625 | $50.21 | $332,641 |
| 2026-05-18 | Senner Christopher J. | -34,901 | $50 | $1,745,050 |
| 2026-05-18 | MORRISSEY MICHAEL | +124,047 | - | - |
| 2026-05-18 | MORRISSEY MICHAEL | -124,047 | - | - |
| 2026-05-15 | Hefti Brenda | -6,411 | $51.1 | $327,602 |
| 2026-05-15 | Aftab Dana | -30,578 | $51.1 | $1,562,536 |
| 2026-05-15 | Haley Patrick J. | -33,265 | $51.1 | $1,699,842 |
| 2026-05-15 | Senner Christopher J. | -40,892 | $51.1 | $2,089,581 |
| 2026-05-15 | MORRISSEY MICHAEL | -128,497 | $51.1 | $6,566,197 |
| 2026-05-07 | Freire Maria C | -20,634 | - | - |
| 2026-05-07 | Freire Maria C | -20,634 | $46 | $949,164 |
| 2026-05-07 | Freire Maria C | +20,634 | $19.77 | $407,934 |
| 2026-05-07 | Beckerle Mary C | -3,856 | - | - |
| 2026-05-07 | Beckerle Mary C | -7,712 | $48.45 | $373,646 |
| 2026-05-07 | Beckerle Mary C | +3,856 | $23.24 | $89,613 |
| 2026-05-07 | POSTE GEORGE | -60,000 | $45.71 | $2,742,600 |
| 2026-05-06 | MORRISSEY MICHAEL | -109,676 | - | - |
| 2026-02-26 | Hefti Brenda | +23,119 | - | - |
| 2026-02-26 | Aftab Dana | +52,018 | - | - |
| 2026-02-26 | Haley Patrick J. | +40,459 | - | - |
| 2026-02-26 | Senner Christopher J. | +52,018 | - | - |
| 2026-02-26 | MORRISSEY MICHAEL | +160,437 | - | - |
| 2026-02-24 | MORRISSEY MICHAEL | -100,278 | - | - |
| 2026-02-24 | Aftab Dana | -47,918 | $44.5 | $2,132,351 |
| 2026-02-19 | Aftab Dana | -29,873 | $44.35 | $1,324,868 |
| 2026-02-18 | WYSZOMIERSKI JACK L | -20,634 | - | - |
| 2026-02-18 | WYSZOMIERSKI JACK L | -99,574 | $44.01 | $4,382,252 |
| 2026-02-18 | WYSZOMIERSKI JACK L | +20,634 | $19.77 | $407,934 |
| 2026-02-18 | Smith Julie | -20,030 | - | - |
| 2026-02-18 | Smith Julie | -44,087 | - | - |
| 2026-02-18 | Smith Julie | -20,030 | $44.3 | $887,329 |
| 2026-02-18 | Smith Julie | +20,030 | $21.69 | $434,451 |
| 2026-02-18 | Smith Julie | -44,087 | $44.5 | $1,961,872 |
| 2026-02-18 | Smith Julie | +44,087 | $19.39 | $854,847 |
| 2026-02-18 | Hefti Brenda | -18,669 | $44.01 | $821,623 |
| 2026-02-18 | MORRISSEY MICHAEL | +125,094 | - | - |
| 2026-02-18 | MORRISSEY MICHAEL | -125,094 | - | - |
| 2026-02-17 | Smith Julie | -42,422 | - | - |
| 2026-02-17 | Smith Julie | -42,422 | $43.33 | $1,838,145 |
| 2026-02-17 | Smith Julie | +42,422 | $18.19 | $771,656 |
| 2026-02-17 | Haley Patrick J. | -64,778 | $43.5 | $2,817,843 |
| 2026-02-17 | Haley Patrick J. | -3,036 | $43.84 | $133,098 |
| 2026-02-17 | Senner Christopher J. | -30,617 | $43.67 | $1,337,044 |
| 2026-02-17 | MORRISSEY MICHAEL | +250,736 | - | - |
| 2026-02-17 | MORRISSEY MICHAEL | -250,736 | - | - |
| 2026-02-15 | Hefti Brenda | -5,430 | $43.92 | $238,486 |
| 2026-02-15 | Aftab Dana | -12,720 | $43.92 | $558,662 |
| 2026-02-15 | Aftab Dana | -26,485 | $43.92 | $1,163,221 |
| 2026-02-15 | Haley Patrick J. | -31,483 | $43.92 | $1,382,733 |
| 2026-02-15 | Senner Christopher J. | -35,870 | $43.92 | $1,575,410 |
| 2026-02-15 | MORRISSEY MICHAEL | -120,390 | $43.92 | $5,287,529 |
| 2026-02-13 | Eckhardt Sue Gail | -3,856 | $43.79 | $168,854 |
| 2026-02-13 | Oliver Bob | -9,088 | - | - |
| 2026-02-13 | Oliver Bob | -21,162 | $43.9 | $929,012 |
| 2026-02-13 | Oliver Bob | -9,088 | $43.61 | $396,328 |
| 2026-02-13 | Oliver Bob | +9,088 | $19.28 | $175,217 |
| 2026-02-13 | Senner Christopher J. | -34,278 | $43 | $1,473,954 |
| 2026-02-13 | MORRISSEY MICHAEL | -494,700 | - | - |
| 2026-02-13 | MORRISSEY MICHAEL | -369,606 | $43.92 | $16,233,096 |
| 2026-02-13 | MORRISSEY MICHAEL | +494,700 | $21.31 | $10,542,057 |
| 2026-01-15 | Aftab Dana | -27,254 | $45.23 | $1,232,698 |
| 2026-01-15 | Aftab Dana | +119,578 | - | - |
| 2026-01-15 | Haley Patrick J. | -32,332 | $45.23 | $1,462,376 |
| 2026-01-15 | Haley Patrick J. | +139,508 | - | - |
| 2026-01-15 | Senner Christopher J. | -40,459 | $45.23 | $1,829,961 |
| 2026-01-15 | Senner Christopher J. | +149,474 | - | - |
| 2026-01-15 | MORRISSEY MICHAEL | -139,524 | $45.23 | $6,310,671 |
| 2026-01-15 | MORRISSEY MICHAEL | +548,073 | - | - |
| 2025-12-03 | Hefti Brenda | +30,170 | - | - |
| 2025-11-25 | Caligan Partners LP | +27,532 | $43.122 | $1,187,235 |
| 2025-11-21 | Aftab Dana | -24,000 | - | - |
| 2025-11-21 | Haley Patrick J. | -28,043 | $42.58 | $1,194,071 |
| 2025-11-20 | Haley Patrick J. | -10,648 | $41.77 | $444,767 |
| 2025-11-20 | Haley Patrick J. | -23,539 | $41.93 | $986,990 |
| 2025-11-20 | Haley Patrick J. | -10,000 | $42.11 | $421,100 |
| 2025-11-17 | Oliver Bob | -1,044 | - | - |
| 2025-11-12 | PAPADOPOULOS STELIOS | -100,000 | $43.55 | $4,355,000 |
| 2025-11-12 | MORRISSEY MICHAEL | -80,000 | - | - |
| 2025-11-12 | MORRISSEY MICHAEL | +101,548 | - | - |
| 2025-11-12 | MORRISSEY MICHAEL | -101,548 | - | - |
| 2025-11-11 | Aftab Dana | -48,383 | $42.5 | $2,056,278 |
| 2025-11-11 | Beckerle Mary C | -5,784 | - | - |
| 2025-11-11 | Beckerle Mary C | -18,838 | $41.9 | $789,312 |
| 2025-11-11 | Beckerle Mary C | -5,784 | $42.03 | $243,102 |
| 2025-11-11 | Beckerle Mary C | +5,784 | $23.24 | $134,420 |
| 2025-11-11 | MORRISSEY MICHAEL | -160,000 | - | - |
| 2025-10-08 | Aftab Dana | +50,673 | - | - |